Bausch Health Cos Inc. (NYSE:BHC) Receives Consensus Rating of “Reduce” from Brokerages

Shares of Bausch Health Cos Inc. (NYSE:BHC) have been given a consensus rating of “Reduce” by the five analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $8.00.

Several equities analysts have recently commented on BHC shares. Wall Street Zen cut shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Barclays reduced their price target on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 25th. Royal Bank Of Canada reduced their price target on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Monday, April 27th. Raymond James Financial reaffirmed a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Finally, Weiss Ratings cut shares of Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th.

Insider Transactions at Bausch Health Cos

In other Bausch Health Cos news, Director Frank D. Lee sold 24,456 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total value of $132,796.08. Following the transaction, the director owned 49,339 shares of the company’s stock, valued at $267,910.77. This trade represents a 33.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Bausch Health Cos

A number of large investors have recently bought and sold shares of the business. Tidal Investments LLC lifted its holdings in Bausch Health Cos by 2.6% in the second quarter. Tidal Investments LLC now owns 50,131 shares of the company’s stock worth $334,000 after acquiring an additional 1,276 shares during the last quarter. Commonwealth Equity Services LLC lifted its holdings in Bausch Health Cos by 14.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 14,067 shares of the company’s stock worth $98,000 after acquiring an additional 1,812 shares during the last quarter. Pictet Asset Management Holding SA lifted its holdings in Bausch Health Cos by 4.1% in the first quarter. Pictet Asset Management Holding SA now owns 54,169 shares of the company’s stock worth $292,000 after acquiring an additional 2,114 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in Bausch Health Cos by 2.5% in the second quarter. CANADA LIFE ASSURANCE Co now owns 104,156 shares of the company’s stock worth $690,000 after acquiring an additional 2,552 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after acquiring an additional 3,106 shares during the last quarter. Institutional investors own 78.65% of the company’s stock.

Bausch Health Cos Stock Performance

Shares of BHC stock opened at $5.47 on Friday. The company has a debt-to-equity ratio of 54.68, a quick ratio of 0.97 and a current ratio of 1.32. Bausch Health Cos has a one year low of $4.41 and a one year high of $8.69. The company’s 50-day simple moving average is $5.42 and its 200-day simple moving average is $6.12. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of -1.69 and a beta of 0.42.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $0.78 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.03). Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%.The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.37 billion. Equities analysts anticipate that Bausch Health Cos will post 4.08 earnings per share for the current fiscal year.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.